关键信息
-
基因名
Transferrin
- 应用
-
别名
CD71; TFR1; P90; TFRC; T9; Trfr; sTfR; Transferrin receptor protein 1, serum form
-
种属
Human
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P02786
-
表达区间
Cys89~Phe760
-
分子量
80kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Transferrin is a crucial glycoprotein involved in iron transport within the bloodstream, playing a vital role in cellular iron homeostasis and overall metabolism. It binds iron ions with high affinity, regulating their availability for essential biological processes. The study of recombinant transferrin has gained significance due to its potential therapeutic applications, particularly in iron deficiency disorders and conditions requiring controlled iron delivery. Recombinant technology allows for the production of transferrin in a laboratory setting, enabling the creation of variants or engineered forms with enhanced properties, such as improved binding affinity or altered release profiles. Such advancements may lead to innovative treatments for diseases associated with abnormal iron metabolism, including anemia, hemochromatosis, and certain cancers. Furthermore, recombinant transferrin can be utilized in drug delivery systems, facilitating the targeted transport of therapeutic agents into specific cells or tissues, particularly cancer cells that often overexpress transferrin receptors. The ongoing research into transferrin and its recombinant forms not only enhances our understanding of iron biology but also opens new avenues for the development of effective and safer therapeutic strategies.
